CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in ...

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

UW Medicine’s Bessie A. Young, MD, MPH, explains how high-risk APOL1 variants, ancestry, and environmental factors shape kidney disease risk.

Providence’s Katherine R. Tuttle, MD, FASN, explains why semaglutide is preferred in T2D and CKD and how guidelines sequence ...

Jordan Feld, MD, MPH, explains how HBsAg testing, NUC therapy, and monitoring capacity will shape access to hepatitis B functional cure. Functional cure lowers the risk of cirrhosis and liver cancer, ...

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

UW Medicine’s Bessie A. Young, MD, MPH, explains how high-risk APOL1 variants, ancestry, and environmental factors shape kidney disease risk. Povetacicept reduced proteinuria by 52% vs 4.3% with ...

Relapse outcomes were largely null in major RCTs, including SOLAR and VIDAMS, despite numerically lower ARR in some analyses ...

Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few ...

As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for ...

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on ...

Sparsentan cut proteinuria about 70% and kept kidney function stable over 2 years in newly diagnosed IgA nephropathy in the SPARTAN study.